HRC
KURA icon

Hoertkorn Richard Charles’s Kura Oncology KURA Stock Holding History

Hoertkorn Richard Charles’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,000
Closed -$20.8K – 79
2025
Q4 		$20.8K Buy
+2,000
New +$21K 0.01% 62

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hoertkorn Richard Charles's KURA Position: Q1 2026 in Review

Hoertkorn Richard Charles sold out of Kura Oncology (KURA) in Q1 2026, closing a stake of 2,000 shares — an estimated $20.8K sold.

Hoertkorn Richard Charles first reported a position in KURA in Q4 2025 and held it in 1 quarter. The position peaked at $20.8K in Q4 2025. 222 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Hoertkorn Richard Charles reported no remaining Kura Oncology position as of Q1 2026 after selling out during the quarter.
  • Hoertkorn Richard Charles sold 2,000 Kura Oncology shares in Q1 2026, an estimated $20.8K.
  • Hoertkorn Richard Charles first reported a position in Kura Oncology in Q4 2025 and held it in 1 quarter.
  • Hoertkorn Richard Charles's Kura Oncology position peaked at $20.8K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Hoertkorn Richard Charles's 13F filing for Q1 2026, filed 30 Apr 2026.